title: Clinical and endoscopic evaluation of gastroesophageal reflux disease in patients successfully treated with esomeprazole.
abstract: BACKGROUND
  Esomeprazole, an S-isomer of omeprazole, is the first proton pump inhibitor developed as an optical isomer, and it has shown high healing rates in erosive esophagitis.
  
  
  OBJECTIVE
  To evaluate the efficacy and tolerability of esomeprazole in subjects with erosive esophagitis, according to the Los Angeles classification study design: an open, multi-center clinical study.
  
  
  METHODS
  Two hundred and eighteen subjects with reflux esophagitis confirmed by endoscopy were included in an open, multi-center study in Brazil. All of them received esomeprazole 40 mg, once daily, for a 4-week period. Subjects who had unhealed esophagitis by week 4 continued the treatment for another 4 weeks. The primary efficacy endpoint was the healing rates by weeks 4 and 8. The secondary endpoints were the number of patients with symptom resolution by week 4, the number of days to sustained symptom resolution, number of symptom-free days and nights and safety and tolerability of the drug.
  
  
  RESULTS
  Healing rates by weeks 4 and 8 were 82% (confidence interval: 77.4%-87.6%) and 96.1% (confidence interval: 93.5% - 98.8%), respectively. Ninety-nine (99%) of the patients had heartburn resolution by week 2. The most common adverse events were headache (4%), diarrhea (2.6%) and epigastric pain (2.2%).
  
  
  CONCLUSIONS
  For the studied period, esomeprazole was shown to be a safe and well-tolerated drug, providing significant healing rates of mucosal breaks, regardless of LA classification, in patients with erosive esophagitis. Esomeprazole was also shown to be effective in quickly relieving symptoms.
authors.affiliation: Universidade Regional de Blumenau, SC. dredson@terra.com.br
authors.forename: Edson Pedro
authors.initials: EP
authors.lastname: da Silva
authors.forename: Farid
authors.initials: F
authors.lastname: Nader
authors.forename: Flavio A
authors.initials: FA
authors.lastname: Quilici
authors.forename: Jaime Natan
authors.initials: JN
authors.lastname: Eisig
authors.forename: Schlioma
authors.initials: S
authors.lastname: Zaterka
authors.forename: Ulysses
authors.initials: U
authors.lastname: Meneghelli
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D016145:Endoscopy, Digestive System; D064098:Esomeprazole / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy / Q000473:pathology; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D064098:Esomeprazole